CD4 and colitis: Using in vitro assays, humanized colitis models, and transcriptomic analyses including single-cell RNA sequencing, we demonstrated that these engineered EVs reprogram inflammatory CD4+ T cells, suppress effector polarization, and enhance FOXP3+ Treg subsets.